The Center for Biosimilars® recaps the top stories for the week of February 10, 2020.
Hi, I’m Christina Mattina for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of February 10, 2020.
Number 5: The European League Against Rheumatism (EULAR) updates guidelines to address recommendations on the use of disease-modifying antirheumatic drugs and glucocorticoids to treat patients with rheumatoid arthritis.
Number 4: Patents on nearly 20 oncology biologics will expire by 2023, which could lead to more biosimilars in cancer care and lower costs, a review article says.
Number 3: At the Specialty Therapies and Biosimilars Congress, a review of the orphan drug market predicts hefty biosimilar competition, although patent struggles need resolution, according to one speaker.
Number 2: Also at the Congress, the director of pharmacy for Emory Healthcare discusses how they developed a strong in-house specialty pharmacy and cut dependence on outside for-profit specialty pharmacies and managed to strengthen adherence and improve patient outcomes.
Number 1: A review of the 2020 pipeline shows oncology biosimilars are starting to gain some traction in the marketplace.
To read all of these articles and more, visit centerforbiosimilars.com.
FDA and Industry Experts Unpack Biosimilar Device Requirements
October 23rd 2024At the GRx+Biosims 2024 conference, a panel of industry experts and FDA officials discussed evolving device requirements for biosimilars and interchangeable biosimilars, highlighting new approaches to comparative use human factors studies, regulatory challenges, and alternative validation methods.
Biosimilars Policy Roundup for September 2024—Podcast Edition
October 6th 2024On this episode of Not So Different, we discuss the FDA's approval of a new biosimilar for treating retinal conditions, which took place in September 2024 alongside other major industry developments, including ongoing legal disputes and broader trends in market dynamics and regulatory challenges.
Unifying Standards: The Need for Streamlined Biosimilar Development
October 22nd 2024At the 2024 GRx+Biosims conference, industry leaders and regulatory experts underscored the urgency of unifying global standards and simplifying the biosimilar development process, sharing insights on recent advancements and the necessity for greater collaboration between manufacturers and regulatory agencies.
Phase 3 Study Reports Similar Efficacy Between SB17, Stelara in Psoriasis
October 19th 2024A phase 3, 28-week comparative clinical trial in patients with moderate to severe plaque psoriasis confirmed similarity of the proposed ustekinumab biosimilar SB17 (Samsung Bioepis) to the reference product (Stelara) in efficacy, safety, pharmacokinetics, and immunogenicity.